Detection of Internal Transcribed Spacer 1 and hsp70 Genetic Markers Using Restriction Fragment Length Polymorphisms and Sequencing in Identification of Leishmania Species Causing Tegumentary Leishmaniasis in Brazil.

The identification of Leishmania species that cause tegumentary leishmaniasis (TL) is important for taxonomic and prognostic purposes. Molecular analysis using different Leishmania genomic targets is the most useful method for identifying Leishmania species. Therefore, we evaluated the performance of ribosomal RNA internal transcribed spacer 1 (ITS1) and heat shock protein (hsp70) genetic markers by polymerase chain reaction (PCR), followed by restriction fragment length polymorphism analysis (RFLP) and sequencing, for identification of Leishmania species. Samples from 84 Brazilian patients were amplified. Internal transcribed spacer 1 PCR followed by RFLP (HaeIII) [ITS1-RFLP (HaeIII)] identified 46.4% (39/84) of the samples as compatible with the Viannia subgenus. Internal transcribed spacer 1 PCR followed by sequencing (ITS1-sequencing) identified Leishmania (Viannia) braziliensis in 91.7% (77/84) of the TL samples, Leishmania (Leishmania) amazonensis in 3.6% (3/84), L. (V.) guyanensis in 2.4% (2/84), and L. (L.) infantum in 1.2% (1/84). One of the samples showed the same proportion of similarity with L. (V.) guyanensis and L. (V.) panamensis. hsp70 nested PCR followed by RFLP (HaeIII) [nested hsp70-RFLP (HaeIII)] identified 91.7% (77/84) of the samples as compatible with L. (V.) braziliensis/L. (V.) naiffi, 3.6% (3/84) with L. (L.) amazonensis, 1.2% (1/84) with L. (L.) infantum, and 3.6% (3/84) with L. (V.) guyanensis. hsp70 PCR followed by sequencing (hsp70-sequencing) identified L. (V.) braziliensis in 91.7% (77/84) of the TL samples, L. (L.) amazonensis in 3.6% (3/84), L. (V.) guyanensis in 3.6% (3/84), and L. (L.) infantum in 1.2% (1/84). Our findings clearly showed that nested hsp70-RFLP (HaeIII) is better than ITS1-RFLP (HaeIII) and that ITS1 or hsp70 PCR followed by sequencing was adequate for identifying Leishmania species. We also found that Leishmania (Viannia) braziliensis is the most common species causing TL in Brazil. Therefore, sequencing multiple target genes such as ITS1 and hsp 70 is more accurate than RFLP for identifying Leishmania species.

Programa de colaboración entre la Farmacia de Atención Primaria y la Farmacia Comunitaria del Collegi Oficial de Farmacèutics de Barcelona. Documento de consenso / Cooperation Program between the Primary Care Pharmacy and the Community Pharmacy of the Official Association of Pharmacists of Barcelona's province: abstract of the consensus document

La colaboración entre el farmacéutico comunitario (FC) y el farmacéutico de atención primaria (FAP) es necesaria para fomentar una política farmacéutica común y coherente que permita ofrecer mensajes únicos e inequívocos a la población. En este artículo presentamos los principales contenidos del documento de consenso "Programa de colaboración Farmacia de Atención Primaria y Farmacia Comunitaria: protocolo de comunicación" del Collegi de Farmacèutics de Barcelona (COFB). Este documento pretende ser una herramienta de ayuda para el FC y para el FAP para implantar una atención farmacéutica integradora e integral en estos dos ámbitos asistenciales. El objetivo principal es establecer canales de coordinación entre profesionales farmacéuticos del ámbito asistencial comunitario y los de la atención primaria (AP) que faciliten la colaboración y mejoren la atención farmacéutica ofrecida a la población. El presente protocolo hace una propuesta de actuación entre la FC y la FAP para cubrir estas necesidades de comunicación. Se trata de analizar las necesidades reales de comunicación, describir los canales utilizables para llevarla a cabo y hacer una propuesta de cómo actuar aplicable en los diferentes contextos. Es una propuesta que define líneas generales de actuación que posteriormente requerirá un desarrollo más detallado y específico según la realidad de cada territorio. El texto ha sido desarrollado de forma consensuada entre farmacéuticos de AP y FC, médicos especialistas en medicina de familia y profesionales expertos del COFB. El grupo de trabajo ha sido liderado por las responsables de las vocalías de Oficina de Farmacia y de la de FAP

The cooperation between the community pharmacist (CP) and the primary care pharmacist (PCP) is necessary to boost a common and coherent drug policy that offers unique and unequivocal messages to the population. In this article we come up with the main contents of the consensus document "Cooperation Program Primary Care Pharmacy and Community Pharmacy: communication protocol" of the Official Association of Pharmacists of Barcelona (OAPB). This document pretends to be a support tool to the CP and to the PCP so that they carry out an integrating pharmaceutical care in this two areas of health. The main objective is to establish coordination channels between pharmacists of the community healthcare area and the ones from the primary care (PCP) in order to facilitate the collaboration and improve the pharmaceutical care offered to the population. This protocol presents a proposal for action between the CP and the PCP to cover all needs of communication. It is based on analysing the real communication needs, describing the channels to communicate and showing a proposal for action suitable in the different contexts. It is a proposal that define the general lines of action. Subsequently, it will need a more detailed and specific development according to the reality of each area. The text have been developed in a consensual way between PCP and CP, doctors specialized in family medicine and skilled professionals of the OAPB. The working group has been headed for the people responsible for the Pharmacy Office and the ones from the PCP

Efficiency of noninvasive sampling methods (swab) together with Polymerase Chain Reaction (PCR) for diagnosing American Tegumentary Leishmaniasis.

Traditional diagnostic methods used to detect American Tegumentary Leishmaniasis, such as histopathology using biopsy samples, culture techniques, and direct search for parasites, have low sensitivity and require invasive collection procedures. This study evaluates the efficiency of noninvasive sampling methods (swab) along with Polymerase Chain Reaction (PCR) for diagnosing American Tegumentary Leishmaniasis using skin and mucous samples from 25 patients who had tested positive for leishmaniasis. The outcome of the tests performance on swab samples was compatible with PCR results on biopsy samples. The findings have also shown that PCR-kDNA test is more efficient than PCR-HSP70 and qPCR tests (sensitivity of 92.3%, 40.7%, and 41%, respectively). Given the high sensitivity of the tests and the fact that the sampling method using swabs affords greater patient comfort and safety, it could be said that this method is a promising alternative to conventional biopsy-based methods for the molecular diagnosis of leishmaniasis.

Efficiency of noninvasive sampling methods (swab) together with Polymerase Chain Reaction (PCR) for diagnosing American Tegumentary Leishmaniasis

ABSTRACT Traditional diagnostic methods used to detect American Tegumentary Leishmaniasis, such as histopathology using biopsy samples, culture techniques, and direct search for parasites, have low sensitivity and require invasive collection procedures. This study evaluates the efficiency of noninvasive sampling methods (swab) along with Polymerase Chain Reaction (PCR) for diagnosing American Tegumentary Leishmaniasis using skin and mucous samples from 25 patients who had tested positive for leishmaniasis. The outcome of the tests performance on swab samples was compatible with PCR results on biopsy samples. The findings have also shown that PCR-kDNA test is more efficient than PCR-HSP70 and qPCR tests (sensitivity of 92.3%, 40.7%, and 41%, respectively). Given the high sensitivity of the tests and the fact that the sampling method using swabs affords greater patient comfort and safety, it could be said that this method is a promising alternative to conventional biopsy-based methods for the molecular diagnosis of leishmaniasis.

Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the new world: A retrospective study

The standard treatment of mucosal leishmaniasis (ML) is pentavalent antimonials, agents with serious adverse effects. Alternative agents include amphotericin B deoxycholate and liposomal amphotericin B. We performed a retrospective study including 29 patients treated with liposomal amphotericin B, most of whom had comorbidities, history of previous treatment of ML, and contraindications to the use of antimonial pentavalent or amphotericin B deoxycholate. We observed a cure rate of 93.1%. Kidney failure was the most important side effect, reported in five patients (17.2%). This study showed a good efficacy and safety profile of liposomal amphotericin B in patients with ML and contraindications to the use of other agents

Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study.

The standard treatment of mucosal leishmaniasis (ML) is pentavalent antimonials, agents with serious adverse effects. Alternative agents include amphotericin B deoxycholate and liposomal amphotericin B. We performed a retrospective study including 29 patients treated with liposomal amphotericin B, most of whom had comorbidities, history of previous treatment of ML, and contraindications to the use of antimonial pentavalent or amphotericin B deoxycholate. We observed a cure rate of 93.1%. Kidney failure was the most important side effect, reported in five patients (17.2%). This study showed a good efficacy and safety profile of liposomal amphotericin B in patients with ML and contraindications to the use of other agents.

Establecimiento de los conocimientos, actitudes y opiniones de la población sobre el uso racional de medicamentos / Establishment of knowledge, attitudes and opinions of general population about rational use of medicines

OBJETIVO: Identificar el nivel de conocimientos, actitudes y opiniones respecto al uso de medicamentos (UM) en población general. MÉTODO: Estudio descriptivo transversal, cuantitativo, realizado en usuarios de la sanidad pública ≥ 18 años asignada a centros de atención primaria de la ciudad de Barcelona. Muestreo bietápico, estratificación: barrio, sexo y edad. Administración presencial de un cuestionario propio validado. Análisis: SPSSv15. Período estudio: diciembre 2011. RESULTADOS: Cuatrocientas ochenta y cuatro encuestas (IC 95%, α = 5%).53% mujeres; 21,3% estudios universitarios. UM : 81% ha tomado medicamentos en los últimos 3 meses; media, 1,9. Conceptos técnicos: El 80% de los que se medican saben indicar qué medicamentos toman y para qué. En el 90% de los casos no saben indicar el nombre del principio activo (pa). El 55,6% no sabe definir el concepto pa. Sólo un 35% reconoce algún pa indicado en el envase de tres medicamentos diferentes y un 44,5% no reconoce ninguno. El 22,7% conoce el significado de contraindicación, efecto adverso e interacción medicamentosa. El 20% tiene total desconocimiento y este aumenta con la edad y disminuye con el nivel de estudios. Opinión y actitud: Valor del indicador global de uso racional (IGUR) de medicamentos, 5,03 puntos: 6,18 praxis, 5,02 información, 3,85 uso sostenible y 3,49 nuevos medicamentos/genéricos. El 70% de los encuestados cree que no se hace un uso racional de medicamentos y el 21,3% cree que es necesaria mayor concienciación social. CONCLUSIONES: Los conocimientos, actitudes y opiniones de los ciudadanos sobre medicamentos son bajos. Es necesario implicar a los ciudadanos y mejorar sus conocimientos básicos para avanzar en el uso racional

OBJECTIVE: Identify the level of knowledge, opinions and attitudes of medicines in general population. METHODS: Descriptive transversal study realised in a sample of ≥ 18 years old public health users from primary health centres in the city of Barcelona. Sample has been chosen using a two phases sampling, stratified by district, gender and age. Questionnaire administered face-to-face. SPSSv15 used for the analysis. Study period: December 2011. RESULTS: 484 surveys has been done (IC 95%, α = 5%).53% were women and 21,3% had university studies. Medicine use: 81% had taken medicines in the last 3 months; average of 2,34. Technical concepts: 80% of medicated people know what they take and its indication.55,6% don't know active ingredient concept. Only 35% recognise the active ingredient showed in the box of the medicine (3 cases shown) and 44,5% not one.22,7% know the meaning of security concepts contraindication, adverse effect and drug interaction.20% ignore. This fact grows with age and reduces with high study levels. Opinion and attitude: Global rational use of medicines indicator obtains 5,03 from 10: 3,42 opinion and 6,51 attitude.70% of people think there is no rational use of medicines in general and 21,3% would promote raising awareness. CONCLUSIONS: Low level of knowledge and poor attitude and opinion in rational use of medicines have been shown in this study. It is necessary involve citizens and improve their basic knowledge to promote rational use of medicines

[Establishment of knowledge, attitudes and opinions of general population about rational use of medicines]. / Establecimiento de los conocimientos, actitudes y opiniones de la población sobre el uso racional de medicamentos.

OBJECTIVE: Identify the level of knowledge, opinions and attitudes of medicines in general population. METHODS: Descriptive transversal study realised in a sample of≥18 years old public health users from primary health centres in the city of Barcelona. Sample has been chosen using a two phases sampling, stratified by district, gender and age. Questionnaire administered face-to-face. SPSSv15 used for the analysis. STUDY PERIOD: December 2011. RESULTS: 484 surveys has been done (IC 95%, α=5%). 53% were women and 21,3% had university studies. Medicine use: 81% had taken medicines in the last 3 months; average of 2,34. TECHNICAL CONCEPTS: 80% of medicated people know what they take and its indication. 55,6% don't know active ingredient concept. Only 35% recognise the active ingredient showed in the box of the medicine (3 cases shown) and 44,5% not one. 22,7% know the meaning of security concepts contraindication, adverse effect and drug interaction. 20% ignore. This fact grows with age and reduces with high study levels. OPINION AND ATTITUDE: Global rational use of medicines indicator obtains 5,03 from 10: 3,42 opinion and 6,51 attitude. 70% of people think there is no rational use of medicines in general and 21,3% would promote raising awareness. CONCLUSIONS: Low level of knowledge and poor attitude and opinion in rational use of medicines have been shown in this study. It is necessary involve citizens and improve their basic knowledge to promote rational use of medicines.

APPLICABILITY OF kDNA-PCR FOR ROUTINE DIAGNOSIS OF AMERICAN TEGUMENTARY LEISHMANIASIS IN A TERTIARY REFERENCE HOSPITAL / Aplicacao do kDNA-PCR para diagnostico de rotina de leishmaniose tegumentar americana em um hospital de referencia

SUMMARY This study evaluated the applicability of kDNA-PCR as a prospective routine diagnosis method for American tegumentary leishmaniasis (ATL) in patients from the Instituto de Infectologia Emílio Ribas (IIER), a reference center for infectious diseases in São Paulo - SP, Brazil. The kDNA-PCR method detected Leishmania DNA in 87.5% (112/128) of the clinically suspected ATL patients, while the traditional methods demonstrated the following percentages of positivity: 62.8% (49/78) for the Montenegro skin test, 61.8% (47/76) for direct investigation, and 19.3% (22/114) for in vitro culture. The molecular method was able to confirm the disease in samples considered negative or inconclusive by traditional laboratory methods, contributing to the final clinical diagnosis and therapy of ATL in this hospital. Thus, we strongly recommend the inclusion of kDNA-PCR amplification as an alternative diagnostic method for ATL, suggesting a new algorithm routine to be followed to help the diagnosis and treatment of ATL in IIER. .

RESUMO Este estudo avaliou a aplicabilidade do kDNA-PCR como método de rotina para diagnóstico de leishmaniose tegumentar americana (ATL) no Instituto de Infectologia Emílio Ribas (IIER), São Paulo, SP, Brasil. O método kDNA-PCR detectou DNA de Leishmania em 87,5% (112/128) dos pacientes com suspeita de ter leishmaniose e, os métodos tradicionais apresentaram as seguintes porcentagens de positividade: 62,8% (49/78) para o teste de Montenegro, 61,8% (47/76) para a pesquisa direta e 19,3% (22/114) para cultura in vitro. O método molecular confirmou a doença em amostras negativas ou inconclusivas pelos métodos laboratoriais tradicionais e, mostrou-se capaz de auxiliar na identificação de infecções causadas pela espécie Leishmania (V.) braziliensis. Além disso, a revisão dos prontuários médicos confirmou a importância do método PCR-RFLP no diagnóstico final de ATL, prognóstico e escolha do tratamento. Assim, recomendamos a inclusão do PCR como método diagnóstico de ATL na rotina hospitalar, e sugerimos um fluxograma para solicitação de exames laboratoriais. .

Applicability of kDNA-PCR for routine diagnosis of American tegumentary leishmaniasis in a tertiary reference hospital.

This study evaluated the applicability of kDNA-PCR as a prospective routine diagnosis method for American tegumentary leishmaniasis (ATL) in patients from the Instituto de Infectologia Emílio Ribas (IIER), a reference center for infectious diseases in São Paulo - SP, Brazil. The kDNA-PCR method detected Leishmania DNA in 87.5% (112/128) of the clinically suspected ATL patients, while the traditional methods demonstrated the following percentages of positivity: 62.8% (49/78) for the Montenegro skin test, 61.8% (47/76) for direct investigation, and 19.3% (22/114) for in vitro culture. The molecular method was able to confirm the disease in samples considered negative or inconclusive by traditional laboratory methods, contributing to the final clinical diagnosis and therapy of ATL in this hospital. Thus, we strongly recommend the inclusion of kDNA-PCR amplification as an alternative diagnostic method for ATL, suggesting a new algorithm routine to be followed to help the diagnosis and treatment of ATL in IIER.

Association of metabolic syndrome and blood pressure nondipping profile in untreated hypertension.

BACKGROUND: There is a marked association between metabolic syndrome (MS) and increased cardiovascular risk. Moreover, nondipping (patients with <10% decline in the asleep relative to the awake blood pressure (BP) mean) has also been associated with increased cardiovascular morbidity and mortality. METHODS: We investigated the association between MS and impaired nocturnal BP decline in 1,770 nondiabetic, untreated hypertensive patients (824 men and 946 women), 48.7 +/- 13.2 years of age. BP was measured by ambulatory monitoring for 48 h to increase reproducibility of the dipping pattern. Physical activity was simultaneously monitored every minute by wrist actigraphy. RESULTS: MS was present in 42.4% of the patients. The prevalence of a nondipper BP profile was significantly higher in patients with MS (46.1% vs. 37.5% in patients without MS, P < 0.001). Patients with MS were characterized by significant elevations in uric acid (5.9 mg/dl vs. 5.2 mg/dl, P < 0.001), fibrinogen (314 mg/dl vs. 304 mg/dl, P = 0.021), and globular sedimentation rate (13.8 mm vs. 11.6 mm, P < 0.001). Nondipping was significantly associated to the presence of MS in a multiple logistic regression model adjusted by other significant confounding factors, including age, serum creatinine, and cigarette smoking. The single most relevant factor in the definition of MS associated to nondipping was elevated waist perimeter. CONCLUSIONS: This study documents a significant increase of a blunted nocturnal BP decline in patients with MS. Patients with MS were also characterized by elevated values of relevant markers of cardiovascular risk, including fibrinogen and globular sedimentation rate.

Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension.

Torasemide is a high-ceiling loop diuretic frequently used in the treatment of congestive heart failure, renal failure, and hypertension. Low doses of torasemide (2.5 to 5 mg/day) do not elevate 24 h natriuresis, and they constitute effective monotherapy for mild-to-moderate uncomplicated essential hypertension according to results based on clinic blood pressure (BP). However, there has yet to be a proper evaluation of its 24 h efficacy or potential dependency of effects according to the circadian time of treatment. Accordingly, this trial investigated the administration time-dependent efficacy of torasemide in uncomplicated essential hypertensive patients. We studied a total of 113 grade 1 and 2 hypertensive patients, 51.7+/-10.6 yrs of age, randomly assigned to receive torasemide (5 mg/day) as a monotherapy either upon awakening or at bedtime. BP was measured by ambulatory monitoring for 48 consecutive hours before and after six weeks of treatment. The efficacy of torasemide was significantly greater with bedtime dosing (i.e., 14.8 and 9.5 mmHg reduction in the 24 h mean systolic and diastolic BP, respectively) as compared with morning dosing upon awakening (i.e., 6.4 and 3.4 mmHg reduction in mean systolic and diastolic BP; p<0.001 between the two treatment-time groups). The percentage of patients with controlled ambulatory BP after treatment was also higher after bedtime treatment (64 vs. 23%; p<0.001). Safety and tolerability were comparable between the two treatment-time groups. A dose of 5 mg/day torasemide is more effective for BP reduction for uncomplicated essential hypertensive patients when ingested at bedtime than in the morning upon arising. The difference in antihypertensive efficacy as a function of the circadian dosing-time of torasemide here documented should be taken into account when prescribing this loop diuretic to treat essential hypertensive patients.

Cronoterapia con torasemida en pacientes hipertensos: aumento de la duración y la eficacia terapéuticas con su administración a la hora de acostarse / Chronotherapy with torasemide in hypertensive patients: increased efficacy and therapeutic coverage with bedtime administration

Fundamento y objetivo: La torasemida es un diurético de asa utilizado con frecuencia en el tratamiento de la insuficiencia cardíaca, la insuficiencia renal y la hipertensión, en función de resultados basados, sobre todo, en la medida clínica de la presión arterial, sin que se haya valorado la eficacia y la duración del fármaco durante las 24 h. Por ello, hemos investigado la eficacia antihipertensiva y los efectos de la torasemida en el perfil circadiano de la presión arterial, administrada a distintas horas en función del ciclo de actividad y descanso. Pacientes y método: Estudiamos a 58 pacientes hipertensos (25 varones y 33 mujeres) con una media (DE) de edad de 48,7 (11,9) años, asignados aleatoriamente a 2 grupos de tratamiento en función del momento de tomar una dosis de 5 mg/día de torasemida: a la hora de levantarse o a la hora de acostarse. La presión arterial se determinó ambulatoriamente durante 48 h consecutivas antes y después de 6 semanas de intervención terapéutica. Resultados: La eficacia de la torasemida fue mayor con la dosis nocturna (11,2 y 8,0 mmHg en la media de 24 h de la presión arterial sistólica y diastólica, respectivamente) que con la matutina (6,2 y 3,7 mmHg de presión sistólica y diastólica). El porcentaje de pacientes con presión arterial ambulatoria controlada fue el doble cuando se administró la torasemida a la hora de acostarse (54%) que cuando se la administró a la hora de levantarse (27%). La duración de la eficacia terapéutica se mantuvo a lo largo de las 24 h sólo cuando se administró la torasemida a la hora de acostarse. Con respecto al perfil de seguridad, 2 pacientes presentaron efectos secundarios (dolor abdominal, diarrea) con la toma matutina y 4 con la nocturna (nicturia). Conclusiones: Una dosis de 5 mg/día de torasemida en monoterapia reduce de forma eficaz la presión arterial cuando se administra el fármaco a la hora de acostarse. Se debe tener en cuenta las diferencias en la eficacia antihipertensiva, la duración del efecto terapéutico y el grado de control en función de la hora de tomar la torasemida cuando se prescriba este diurético de asa en el tratamiento de pacientes con hipertensión arterial esencial

Background and objective: Torasemide is a high ceiling loop diuretic frequently used for treatment of heart failure, renal failure and hypertension, according to results mainly based on clinic blood pressure measurements, without proper evaluation of the 24-hour efficacy of the drug. Accordingly, we investigated the time-dependent antihypertensive efficacy of torasemide in hypertensive patients. Patients and method: We studied 58 patients with grade 1-2 essential hypertension (25 men and 33 women), 48.7 (11.9) years of age, randomly assigned to receive torasemide (5 mg/day) either upon awakening or at bedtime. Blood pressure was measured by ambulatory monitoring for 48 consecutive hours before and after 6 weeks of therapy. Results: Efficacy of torasemide was significantly higher with bedtime dosing (11.2 and 8.0 mmHg reduction in the 24-hour mean of systolic and diastolic blood pressure, respectively) as compared to the administration of the drug on awakening (6.2 and 3.7 mmHg reduction in systolic and diastolic blood pressure). The percentage of patients with controlled ambulatory blood pressure after treatment was also higher after bedtime treatment (54% versus 27%). The time-response curves indicate a full 24-hour therapeutic duration only when torasemide was administered before bedtime. With regard to the safety profile, 2 patients presented secondary effects (abdominal pain, diarrhea) in morning dose, and 4 patients taking the drug at bedtime reported nicturia. Conclusions: A dose of 5 mg/day torasemide is effective for blood pressure reduction after bedtime administration. The differences in efficacy and therapeutic duration as a function of the circadian time of treatment with torasemide here documented should be taken into account when prescribing this loop diuretic for treatment of patients with essential hypertension

Evaluation of the concordance of sialometry and salivary glands scintigraphy in dry mouth patients.

INTRODUCTION: Many diagnostic tests are used to evaluate dry mouth patients, especially the ones with Sjögren's Syndrome, to whom these tests are part of classification criteria for scientific studies. AIM: Thus, the concordance between results of sialometry and salivary glands scintigraphy was evaluated; if positive, it would enable the choice of one or the other for diagnosis. PATIENTS AND METHOD: Seventy-two dry mouth patients were divided into non-Sjögren's Syndrome group, primary Sjögren's Syndrome group and secondary Sjögren's Syndrome group. The concordance among sialometry and scintigraphy results was evaluated by Kappa test. RESULTS: It was observed that their concordance was equal or near to zero. CONCLUSION: It is not possible to make a choice between these tests and both should be performed.

Avaliação da concordância da sialometria e cintilografia de glândulas salivares em pacientes com boca seca / Evaluation of the concordance of sialometry and salivary glands scintigraphy in dry mouth patients

INTRODUÇÃO: São utilizados vários exames para avaliar os pacientes com queixa de boca seca e, especialmente, os pacientes com Síndrome de Sjõgren, em que estes exames fazem parte de critérios de classificação para estudos científicos. OBJETIVO: Desta maneira, procurou-se avaliar se haveria concordância entre os resultados da sialometria e da cintilografia de glândulas salivares para, se esta concordância estiver presente, optar por apenas um dos dois exames. CASUíSTICA E MÉTODO: Foram avaliados 72 pacientes com boca seca, divididos em grupos não-Síndrome de Sjõgren, com Síndrome de Sjõgren primária e com Síndrome de Sjõgren secundária. Os resultados de sialometria e cintilografia de glândulas salivares foram estudados, procurando-se dimensionar a concordância existente entre eles, através do teste de Kappa. RESULTADOS: Observou-se concordância igual ou próxima de zero entre os dois testes. CONCLUSÃO: Pelos resultados observados, não é possível fazer a opção por um ou outro exame, devendo ambos serem realizados.

INTRODUCTION: Many diagnostic tests are used to evaluate dry mouth patients, especially the ones with SjõgrenÆs Syndrome, to whom these tests are part of classification criteria for scientific studies. AIM: Thus, the concordance between results of sialometry and salivary glands scintigraphy was evaluated; if positive, it would enable the choice of one or the other for diagnosis. PATIENTS AND METHOD: Seventy-two dry mouth patients were divided into non-SjõgrenÆs Syndrome group, primary SjõgrenÆs Syndrome group and secondary SjõgrenÆs Syndrome group. The concordance among sialometry and scintigraphy results was evaluated by Kappa test. RESULTS: It was observed that their concordance was equal or near to zero. CONCLUSION: It is not possible to make a choice between these tests and both should be performed.

[Chronotherapy with torasemide in hypertensive patients: increased efficacy and therapeutic coverage with bedtime administration]. / Cronoterapia con torasemida en pacientes hipertensos: aumento de la duración y la eficacia terapéuticas con su administración a la hora de acostarse.

BACKGROUND AND OBJECTIVE: Torasemide is a high ceiling loop diuretic frequently used for treatment of heart failure, renal failure and hypertension, according to results mainly based on clinic blood pressure measurements, without proper evaluation of the 24-hour efficacy of the drug. Accordingly, we investigated the time-dependent antihypertensive efficacy of torasemide in hypertensive patients. PATIENTS AND METHOD: We studied 58 patients with grade 1-2 essential hypertension (25 men and 33 women), 48.7 (11.9) years of age, randomly assigned to receive torasemide (5 mg/day) either upon awakening or at bedtime. Blood pressure was measured by ambulatory monitoring for 48 consecutive hours before and after 6 weeks of therapy. RESULTS: Efficacy of torasemide was significantly higher with bedtime dosing (11.2 and 8.0 mmHg reduction in the 24-hour mean of systolic and diastolic blood pressure, respectively) as compared to the administration of the drug on awakening (6.2 and 3.7 mmHg reduction in systolic and diastolic blood pressure). The percentage of patients with controlled ambulatory blood pressure after treatment was also higher after bedtime treatment (54% versus 27%). The time-response curves indicate a full 24-hour therapeutic duration only when torasemide was administered before bedtime. With regard to the safety profile, 2 patients presented secondary effects (abdominal pain, diarrhea) in morning dose, and 4 patients taking the drug at bedtime reported nicturia. CONCLUSIONS: A dose of 5 mg/day torasemide is effective for blood pressure reduction after bedtime administration. The differences in efficacy and therapeutic duration as a function of the circadian time of treatment with torasemide here documented should be taken into account when prescribing this loop diuretic for treatment of patients with essential hypertension.

Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects.

Previous results have indicated that valsartan administration at bed-time, as opposed to upon wakening, improves the diurnal/nocturnal ratio of blood pressure (BP) toward a normal dipping pattern, without loss of 24 h efficacy. This ratio is characterized by a progressive decrease with aging. Accordingly, we investigated the administration time-dependent antihypertensive efficacy of valsartan, an angiotensin blocking agent, in elderly hypertensive patients. We studied 100 elderly patients with grade 1-2 essential hypertension (34 men and 66 women), 68.2+/-4.9 years of age, randomly assigned to receive valsartan (160 mg/d) as a monotherapy either upon awakening or at bed-time. BP was measured for 48 h by ambulatory monitoring, at 20 min intervals between 07:00 to 23:00 h and at 30 min intervals at night, before and after 3 months of therapy. Physical activity was simultaneously monitored every minute by wrist actigraphy to accurately determine the duration of sleep and wake spans to enable the accurate calculation of the diurnal and nocturnal means of BP for each subject. There was a highly significant BP reduction after 3 months of valsartan treatment (p < 0.001). The reduction was slightly larger with bed-time dosing (15.3 and 9.2 mm Hg reduction in the 24 h mean of systolic and diastolic BP, respectively) than with morning dosing (12.3 and 6.3 mm Hg reduction in the 24 h mean of systolic and diastolic BP, respectively). The diurnal/nocturnal ratio, measured as the nocturnal decline of BP relative to the diurnal mean, was unchanged in the group ingesting valsartan upon awakening (-1.0 and -0.3 for systolic and diastolic BP; p > 0.195). This ratio was significantly increased (6.6 and 5.4 for systolic and diastolic BP; p < 0.001) when valsartan was ingested at bed-time. The reduction of the nocturnal mean was doubled in the group ingesting valsartan at bed-time, as compared to the group ingesting it in the morning (p < 0.001). In elderly hypertensive patients, mainly characterized by a diminished nocturnal decline in BP, bed-time valsartan dosing is better than morning dosing since it improves efficacy during the nighttime sleep span, with the potential reduction in cardiovascular risk that has been associated with a normalized diurnal/nocturnal BP ratio.

Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension.

Patients with resistant hypertension present high prevalence of a non-dipper blood pressure pattern. Recent results indicate that non-dipping is related partly to the absence of 24-hour therapeutic coverage in patients treated with single morning doses. Accordingly, we investigated the impact of treatment time on the blood pressure pattern in 700 patients with resistant hypertension on the basis of clinic measurements who were studied by 48-hour ambulatory monitoring. Among them, 299 patients received all their medication on awakening, and 401 were taking > or =1 antihypertensive drug at bedtime. The percentage of patients with controlled ambulatory blood pressure was double in patients taking 1 drug at bedtime (P=0.008). Among the 578 patients with true resistant hypertension, subjects receiving 1 drug at bedtime showed a significant reduction in the 24-hour mean of systolic and diastolic blood pressure (3.1 and 1.6 mm Hg, respectively; P<0.011). This reduction was much more prominent during nighttime (5.1 and 3.0 mm Hg; P<0.001). Accordingly, the diurnal/nocturnal blood pressure ratio was significantly increased by 2.7 and the prevalence on non-dipping reduced (56.9 versus 81.9%; P<0.001) in patients taking 1 drug at bedtime. Compared with patients receiving all drugs on awakening, subjects with 1 drug at bedtime also showed significant reductions in the average values of glucose, cholesterol, fibrinogen, and urinary albumin excretion (P<0.011). In patients with resistant hypertension, pharmacological therapy should take into account when to treat with respect to the rest-activity cycle of each patient to improve control and to avoid the non-dipper pattern associated to higher cardiovascular risk.

Manifestações de linfoma na síndrome de Sjõgren: existe relação?

A Síndrome de Sjõgren (SS) é considerada uma afecção multissistêmica, crônica, que se caracteriza pela infiltração linfocítica nas glândulas exócrinas e a produção de auto-anticorpos. OBJETIVO: Vários estudos têm notado um aumento na incidência de linfomas malignos em pacientes com SS. Em nosso estudo tentamos descrever esta relação. FORMA DE ESTUDO: Coorte transversal. MATERIAL E MÉTODO: Pacientes com Síndrome Sicca acompanhados no ambulatório de Estomatologia do Departamento de Otorrinolaringologia da Santa Casa de Misericórdia de São Paulo, no período de julho de 1999 a abril de 2002. RESULTADOS: Dos 39 pacientes, 24 foram classificados com SS. A idade variou de 19 a 83 anos, com predominância do sexo feminino (69,7 por cento). O intervalo de tempo entre o início dos sintomas e o diagnóstico de SS variou de 3,77 anos. Não foi observado desenvolvimento de linfoma em nenhum dos pacientes avaliados. CONCLUSÃO: O diagnóstico de SS e o aumento do risco de desenvolvimento de Linfoma ao longo dos anos são importantes, então um longo período de seguimento destes pacientes é fundamental. Observamos que nossos achados foram diferentes quando comparados com a literatura. Nós não encontramos nenhum linfoma em nossos pacientes.

Endoscopia nasossinusal associada à tomografia computadorizada dos seios paranasais no diagnóstico de obstrução nasal crônica

A obstrução nasal crônica é uma queixa comum na prática ambulatorial nos consultórios de otorrinolaringologia. O diagnóstico de obstrução nasal é fundamentado na história clínica, exame físico e exames complementares. Dentre estes, já é firmada na literatura atual a importância da endoscopia nasossinusal e da tomografia computadorizada. OBJETIVO: O objetivo desse trabalho se baseia em um estudo comparativo entre achados da endoscopia nasossinusal e da TC dos seios paranasais, dentro da propedêutica da investigação etiológica da obstrução nasal crônica, individualizando a importância de cada exame para conclusão diagnóstica. FORMA DE ESTUDO: Coorte histórica. MATERIAL E MÉTODO: Foram estudados 20 pacientes com queixa de obstrução nasal crônica, de idades entre 14 e 51 anos, do Serviço Ambulatorial de Otorrinolaringologia do Hospital Nossa Senhora de Lourdes, São Paulo, capital, em um estudo clínico retrospectivo, realizado através de revisão de prontuários de pacientes atendidos de 2002 a 2004. Todos os pacientes apresentavam queixa de obstrução nasal crônica. RESULTADO: Dos 20 pacientes, 10 (50 por cento) apresentavam queixas alérgicas associadas. Em 16 dos 20 pacientes (80 por cento) foi encontrada hipertrofia de cornetos evidenciada pela nasofibroscopia; em apenas 9 dos 20 pacientes (45 por cento) foi encontrada a mesma alteração à TC. Com base nos resultados apresentados, o achado de hipertrofia de cornetos foi mais evidenciado à nasofibroscopia que à TC (80 por cento X 45 por cento). Dois casos de polipose nasal foram evidenciados à nasofibroscopia não sendo à TC, além de dois outros casos onde não foram observadas alterações à TC, sendo estas verificadas à nasofibroscopia, ou seja, TC normal com alterações à nasofibroscopia. CONCLUSÃO: Assim, diante do estudo apresentado e dos resultados obtidos pôde-se observar que, em âmbito das fossas nasais, os achados obtidos pela endoscopia nasossinusal foram mais conclusivos na elucidação diagnóstica do que os obtidos através da tomografia computadorizada dos seios paranasais.